{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:29:39Z","timestamp":1789655379099,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejpn.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T21:17:54Z","timestamp":1656105474000},"page":"5-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Rituximab in juvenile myasthenia gravis-an international cohort study and literature review"],"prefix":"10.1016","volume":"40","author":[{"given":"Sithara","family":"Ramdas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Della Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"McWilliam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jacquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Alabaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Parasuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Jungbluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2022.06.009_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3389\/fneur.2020.00743","article-title":"Management of juvenile myasthenia gravis","volume":"11","author":"O'Connell","year":"2020","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2022.06.009_bib2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.ejpn.2022.06.009_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.nmd.2019.11.008","article-title":"Paediatric myasthenia gravis: prognostic factors for drug free remission","volume":"30","author":"Vecchio","year":"2020","journal-title":"Neuromuscul. Disord."},{"issue":"5 Pt 1","key":"10.1016\/j.ejpn.2022.06.009_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am. J. Transplant."},{"issue":"2","key":"10.1016\/j.ejpn.2022.06.009_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.06.009_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review. Journal of Neurology","volume":"91","author":"Di Stefano","year":"2020","journal-title":"Neurosurg. Psychiatr."},{"key":"10.1016\/j.ejpn.2022.06.009_bib7","doi-asserted-by":"crossref","first-page":"603e609","DOI":"10.1002\/mus.25965","article-title":"Clinical features and evolution of juvenile myasthenia gravis in a French cohort","volume":"57","author":"Barraud","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejpn.2022.06.009_bib8","doi-asserted-by":"crossref","first-page":"651e652","DOI":"10.1016\/j.nmd.2015.03.014","article-title":"Selective response to rituximab in a young child with MuSK-associated myasthenia gravis","volume":"25","author":"Govindarajan","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2022.06.009_bib9","doi-asserted-by":"crossref","DOI":"10.18295\/squmj.2018.18.02.018","article-title":"Rituximab treatment in myasthaenia gravis: report of two paediatric cases","volume":"18","author":"Koul","year":"2018","journal-title":"Sultan Qaboos Univ. Med. J."},{"issue":"3","key":"10.1016\/j.ejpn.2022.06.009_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pediatrneurol.2012.05.017","article-title":"Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature","volume":"47","author":"Koul","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ejpn.2022.06.009_bib11","unstructured":"Zingariello CD, Melissa EE, Kang PB. Rituximab as adjunct maintenance therapy for refractory juvenile myasthenia gravis. Pediatr Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2022.06.009_bib12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpn.2022.06.009_bib13","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.4076\/1757-1626-2-6609","article-title":"Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series","volume":"2","author":"Tzaribachev","year":"2009","journal-title":"Cases J."},{"issue":"11","key":"10.1016\/j.ejpn.2022.06.009_bib14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.nmd.2013.07.010","article-title":"Muscle specific kinase autoimmune myasthenia gravis in children: a case series","volume":"23","author":"Skjei","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejpn.2022.06.009_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/2576117X.2019.1578164","article-title":"Longstanding and refractory anti-muscle specific tyrosine kinase antibody-associated myasthenia gravis (Anti-MuSK-MG) in a child successfully treated with rituximab","volume":"69","author":"Weger","year":"2019","journal-title":"J. Binocul. Vis. Ocul. Motil."},{"issue":"4","key":"10.1016\/j.ejpn.2022.06.009_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis\u2013experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.ejpn.2022.06.009_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2022.06.009_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.06.009_bib19","first-page":"e2182","article-title":"2018 Emerging science abstracts: B-cell targeted treatment in myasthenia gravis (BeatMG) - a phase 2 trial of rituximab in myasthenia gravis: topline results","volume":"90","author":"Nowak","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ejpn.2022.06.009_bib20","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejpn.2022.06.009_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jpeds.2017.05.002","article-title":"Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review","volume":"187","author":"Mahmoud","year":"2017","journal-title":"J. Pediatr."},{"issue":"10","key":"10.1016\/j.ejpn.2022.06.009_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520962348","article-title":"Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis","volume":"48","author":"Qu","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.ejpn.2022.06.009_bib23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/0961203315578764","article-title":"Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus","volume":"24","author":"Olfat","year":"2015","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.ejpn.2022.06.009_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-019-0365-y","article-title":"Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases","volume":"17","author":"Khojah","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"4","key":"10.1016\/j.ejpn.2022.06.009_bib25","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1212\/NXI.0000000000000724","article-title":"Single-cycle rituximab-induced immunologic changes in children: enhanced in neuroimmunologic disease?","volume":"7","author":"Dey\u00e0-Mart\u00ednez","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:39:04Z","timestamp":1761071944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":25,"alternative-id":["S1090379822000964"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.009","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in juvenile myasthenia gravis-an international cohort study and literature review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}